nodes	percent_of_prediction	percent_of_DWPC	metapath
Naratriptan—migraine—Acetylsalicylic acid—coronary artery disease	0.497	1	CpDpCtD
Naratriptan—HTR1B—Penbutolol—coronary artery disease	0.134	0.615	CbGbCtD
Naratriptan—HTR1A—Penbutolol—coronary artery disease	0.0839	0.385	CbGbCtD
Naratriptan—Eletriptan—HTR7—coronary artery disease	0.000527	0.414	CrCbGaD
Naratriptan—Almotriptan—CYP2C19—coronary artery disease	0.000419	0.329	CrCbGaD
Naratriptan—Eletriptan—CYP2C19—coronary artery disease	0.000327	0.257	CrCbGaD
Naratriptan—Constipation—Furosemide—coronary artery disease	6.06e-05	0.000319	CcSEcCtD
Naratriptan—Hypersensitivity—Niacin—coronary artery disease	6.05e-05	0.000318	CcSEcCtD
Naratriptan—Ill-defined disorder—Lisinopril—coronary artery disease	6.04e-05	0.000318	CcSEcCtD
Naratriptan—Discomfort—Ramipril—coronary artery disease	6.04e-05	0.000318	CcSEcCtD
Naratriptan—Asthenia—Olmesartan—coronary artery disease	6.03e-05	0.000317	CcSEcCtD
Naratriptan—Headache—Clopidogrel—coronary artery disease	6.03e-05	0.000317	CcSEcCtD
Naratriptan—Rash—Lovastatin—coronary artery disease	6.03e-05	0.000317	CcSEcCtD
Naratriptan—Dermatitis—Lovastatin—coronary artery disease	6.03e-05	0.000317	CcSEcCtD
Naratriptan—Anaemia—Lisinopril—coronary artery disease	6.02e-05	0.000317	CcSEcCtD
Naratriptan—Feeling abnormal—Perindopril—coronary artery disease	6.01e-05	0.000316	CcSEcCtD
Naratriptan—Headache—Lovastatin—coronary artery disease	5.99e-05	0.000315	CcSEcCtD
Naratriptan—Pruritus—Valsartan—coronary artery disease	5.98e-05	0.000314	CcSEcCtD
Naratriptan—Dry mouth—Ramipril—coronary artery disease	5.98e-05	0.000314	CcSEcCtD
Naratriptan—Myalgia—Timolol—coronary artery disease	5.98e-05	0.000314	CcSEcCtD
Naratriptan—Arthralgia—Timolol—coronary artery disease	5.98e-05	0.000314	CcSEcCtD
Naratriptan—Vomiting—Ezetimibe—coronary artery disease	5.97e-05	0.000314	CcSEcCtD
Naratriptan—Hypersensitivity—Pravastatin—coronary artery disease	5.96e-05	0.000313	CcSEcCtD
Naratriptan—Anxiety—Timolol—coronary artery disease	5.96e-05	0.000313	CcSEcCtD
Naratriptan—Pruritus—Olmesartan—coronary artery disease	5.95e-05	0.000313	CcSEcCtD
Naratriptan—Body temperature increased—Captopril—coronary artery disease	5.93e-05	0.000312	CcSEcCtD
Naratriptan—Dizziness—Simvastatin—coronary artery disease	5.92e-05	0.000311	CcSEcCtD
Naratriptan—Rash—Ezetimibe—coronary artery disease	5.92e-05	0.000311	CcSEcCtD
Naratriptan—Dermatitis—Ezetimibe—coronary artery disease	5.91e-05	0.000311	CcSEcCtD
Naratriptan—Confusional state—Ramipril—coronary artery disease	5.91e-05	0.000311	CcSEcCtD
Naratriptan—Discomfort—Timolol—coronary artery disease	5.91e-05	0.000311	CcSEcCtD
Naratriptan—Asthenia—Niacin—coronary artery disease	5.9e-05	0.00031	CcSEcCtD
Naratriptan—Fatigue—Losartan—coronary artery disease	5.89e-05	0.00031	CcSEcCtD
Naratriptan—Headache—Ezetimibe—coronary artery disease	5.88e-05	0.000309	CcSEcCtD
Naratriptan—Malaise—Lisinopril—coronary artery disease	5.87e-05	0.000309	CcSEcCtD
Naratriptan—Oedema—Ramipril—coronary artery disease	5.86e-05	0.000308	CcSEcCtD
Naratriptan—Anaphylactic shock—Ramipril—coronary artery disease	5.86e-05	0.000308	CcSEcCtD
Naratriptan—Vertigo—Lisinopril—coronary artery disease	5.85e-05	0.000308	CcSEcCtD
Naratriptan—Dry mouth—Timolol—coronary artery disease	5.85e-05	0.000307	CcSEcCtD
Naratriptan—Pain—Losartan—coronary artery disease	5.85e-05	0.000307	CcSEcCtD
Naratriptan—Constipation—Losartan—coronary artery disease	5.85e-05	0.000307	CcSEcCtD
Naratriptan—Syncope—Lisinopril—coronary artery disease	5.84e-05	0.000307	CcSEcCtD
Naratriptan—Vomiting—Eplerenone—coronary artery disease	5.84e-05	0.000307	CcSEcCtD
Naratriptan—Feeling abnormal—Furosemide—coronary artery disease	5.84e-05	0.000307	CcSEcCtD
Naratriptan—Nausea—Fenofibrate—coronary artery disease	5.82e-05	0.000306	CcSEcCtD
Naratriptan—Pruritus—Niacin—coronary artery disease	5.81e-05	0.000306	CcSEcCtD
Naratriptan—Asthenia—Pravastatin—coronary artery disease	5.81e-05	0.000305	CcSEcCtD
Naratriptan—Rash—Eplerenone—coronary artery disease	5.79e-05	0.000305	CcSEcCtD
Naratriptan—Urticaria—Perindopril—coronary artery disease	5.79e-05	0.000304	CcSEcCtD
Naratriptan—Hypersensitivity—Trandolapril—coronary artery disease	5.79e-05	0.000304	CcSEcCtD
Naratriptan—Dermatitis—Eplerenone—coronary artery disease	5.79e-05	0.000304	CcSEcCtD
Naratriptan—Diarrhoea—Valsartan—coronary artery disease	5.78e-05	0.000304	CcSEcCtD
Naratriptan—Confusional state—Timolol—coronary artery disease	5.78e-05	0.000304	CcSEcCtD
Naratriptan—Shock—Ramipril—coronary artery disease	5.77e-05	0.000303	CcSEcCtD
Naratriptan—Hypersensitivity—Enalapril—coronary artery disease	5.77e-05	0.000303	CcSEcCtD
Naratriptan—Body temperature increased—Perindopril—coronary artery disease	5.76e-05	0.000303	CcSEcCtD
Naratriptan—Palpitations—Lisinopril—coronary artery disease	5.76e-05	0.000303	CcSEcCtD
Naratriptan—Diarrhoea—Olmesartan—coronary artery disease	5.76e-05	0.000303	CcSEcCtD
Naratriptan—Headache—Eplerenone—coronary artery disease	5.75e-05	0.000303	CcSEcCtD
Naratriptan—Nervous system disorder—Ramipril—coronary artery disease	5.75e-05	0.000302	CcSEcCtD
Naratriptan—Thrombocytopenia—Ramipril—coronary artery disease	5.74e-05	0.000302	CcSEcCtD
Naratriptan—Anaphylactic shock—Timolol—coronary artery disease	5.73e-05	0.000301	CcSEcCtD
Naratriptan—Oedema—Timolol—coronary artery disease	5.73e-05	0.000301	CcSEcCtD
Naratriptan—Pruritus—Pravastatin—coronary artery disease	5.72e-05	0.000301	CcSEcCtD
Naratriptan—Loss of consciousness—Lisinopril—coronary artery disease	5.72e-05	0.000301	CcSEcCtD
Naratriptan—Nausea—Clopidogrel—coronary artery disease	5.72e-05	0.000301	CcSEcCtD
Naratriptan—Skin disorder—Ramipril—coronary artery disease	5.69e-05	0.000299	CcSEcCtD
Naratriptan—Infection—Timolol—coronary artery disease	5.69e-05	0.000299	CcSEcCtD
Naratriptan—Vomiting—Simvastatin—coronary artery disease	5.69e-05	0.000299	CcSEcCtD
Naratriptan—Hypersensitivity—Telmisartan—coronary artery disease	5.69e-05	0.000299	CcSEcCtD
Naratriptan—Cough—Lisinopril—coronary artery disease	5.68e-05	0.000299	CcSEcCtD
Naratriptan—Nausea—Lovastatin—coronary artery disease	5.68e-05	0.000299	CcSEcCtD
Naratriptan—Hyperhidrosis—Ramipril—coronary artery disease	5.67e-05	0.000298	CcSEcCtD
Naratriptan—Rash—Simvastatin—coronary artery disease	5.64e-05	0.000297	CcSEcCtD
Naratriptan—Dermatitis—Simvastatin—coronary artery disease	5.64e-05	0.000296	CcSEcCtD
Naratriptan—Asthenia—Trandolapril—coronary artery disease	5.64e-05	0.000296	CcSEcCtD
Naratriptan—Shock—Timolol—coronary artery disease	5.64e-05	0.000296	CcSEcCtD
Naratriptan—Feeling abnormal—Losartan—coronary artery disease	5.63e-05	0.000296	CcSEcCtD
Naratriptan—Urticaria—Furosemide—coronary artery disease	5.63e-05	0.000296	CcSEcCtD
Naratriptan—Diarrhoea—Niacin—coronary artery disease	5.62e-05	0.000296	CcSEcCtD
Naratriptan—Nervous system disorder—Timolol—coronary artery disease	5.62e-05	0.000296	CcSEcCtD
Naratriptan—Asthenia—Enalapril—coronary artery disease	5.62e-05	0.000295	CcSEcCtD
Naratriptan—Headache—Simvastatin—coronary artery disease	5.61e-05	0.000295	CcSEcCtD
Naratriptan—Body temperature increased—Furosemide—coronary artery disease	5.6e-05	0.000295	CcSEcCtD
Naratriptan—Dizziness—Valsartan—coronary artery disease	5.59e-05	0.000294	CcSEcCtD
Naratriptan—Nausea—Ezetimibe—coronary artery disease	5.57e-05	0.000293	CcSEcCtD
Naratriptan—Skin disorder—Timolol—coronary artery disease	5.57e-05	0.000293	CcSEcCtD
Naratriptan—Dizziness—Olmesartan—coronary artery disease	5.56e-05	0.000293	CcSEcCtD
Naratriptan—Pruritus—Trandolapril—coronary artery disease	5.56e-05	0.000292	CcSEcCtD
Naratriptan—Myalgia—Lisinopril—coronary artery disease	5.55e-05	0.000292	CcSEcCtD
Naratriptan—Arthralgia—Lisinopril—coronary artery disease	5.55e-05	0.000292	CcSEcCtD
Naratriptan—Hyperhidrosis—Timolol—coronary artery disease	5.54e-05	0.000291	CcSEcCtD
Naratriptan—Asthenia—Telmisartan—coronary artery disease	5.54e-05	0.000291	CcSEcCtD
Naratriptan—Pruritus—Enalapril—coronary artery disease	5.54e-05	0.000291	CcSEcCtD
Naratriptan—Diarrhoea—Pravastatin—coronary artery disease	5.54e-05	0.000291	CcSEcCtD
Naratriptan—Anxiety—Lisinopril—coronary artery disease	5.53e-05	0.000291	CcSEcCtD
Naratriptan—Discomfort—Lisinopril—coronary artery disease	5.48e-05	0.000288	CcSEcCtD
Naratriptan—Hypotension—Ramipril—coronary artery disease	5.48e-05	0.000288	CcSEcCtD
Naratriptan—Pruritus—Telmisartan—coronary artery disease	5.46e-05	0.000287	CcSEcCtD
Naratriptan—Nausea—Eplerenone—coronary artery disease	5.46e-05	0.000287	CcSEcCtD
Naratriptan—Dizziness—Niacin—coronary artery disease	5.43e-05	0.000286	CcSEcCtD
Naratriptan—Urticaria—Losartan—coronary artery disease	5.43e-05	0.000286	CcSEcCtD
Naratriptan—Dry mouth—Lisinopril—coronary artery disease	5.42e-05	0.000285	CcSEcCtD
Naratriptan—Body temperature increased—Losartan—coronary artery disease	5.4e-05	0.000284	CcSEcCtD
Naratriptan—Asthenia—Captopril—coronary artery disease	5.39e-05	0.000283	CcSEcCtD
Naratriptan—Diarrhoea—Trandolapril—coronary artery disease	5.38e-05	0.000283	CcSEcCtD
Naratriptan—Vomiting—Valsartan—coronary artery disease	5.37e-05	0.000283	CcSEcCtD
Naratriptan—Confusional state—Lisinopril—coronary artery disease	5.36e-05	0.000282	CcSEcCtD
Naratriptan—Diarrhoea—Enalapril—coronary artery disease	5.35e-05	0.000282	CcSEcCtD
Naratriptan—Hypotension—Timolol—coronary artery disease	5.35e-05	0.000282	CcSEcCtD
Naratriptan—Dizziness—Pravastatin—coronary artery disease	5.35e-05	0.000281	CcSEcCtD
Naratriptan—Vomiting—Olmesartan—coronary artery disease	5.35e-05	0.000281	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Ramipril—coronary artery disease	5.34e-05	0.000281	CcSEcCtD
Naratriptan—Rash—Valsartan—coronary artery disease	5.33e-05	0.00028	CcSEcCtD
Naratriptan—Dermatitis—Valsartan—coronary artery disease	5.32e-05	0.00028	CcSEcCtD
Naratriptan—Nausea—Simvastatin—coronary artery disease	5.32e-05	0.00028	CcSEcCtD
Naratriptan—Anaphylactic shock—Lisinopril—coronary artery disease	5.32e-05	0.00028	CcSEcCtD
Naratriptan—Oedema—Lisinopril—coronary artery disease	5.32e-05	0.00028	CcSEcCtD
Naratriptan—Pruritus—Captopril—coronary artery disease	5.31e-05	0.000279	CcSEcCtD
Naratriptan—Rash—Olmesartan—coronary artery disease	5.3e-05	0.000279	CcSEcCtD
Naratriptan—Dermatitis—Olmesartan—coronary artery disease	5.3e-05	0.000279	CcSEcCtD
Naratriptan—Headache—Valsartan—coronary artery disease	5.29e-05	0.000278	CcSEcCtD
Naratriptan—Diarrhoea—Telmisartan—coronary artery disease	5.28e-05	0.000278	CcSEcCtD
Naratriptan—Infection—Lisinopril—coronary artery disease	5.28e-05	0.000278	CcSEcCtD
Naratriptan—Headache—Olmesartan—coronary artery disease	5.27e-05	0.000277	CcSEcCtD
Naratriptan—Paraesthesia—Ramipril—coronary artery disease	5.26e-05	0.000277	CcSEcCtD
Naratriptan—Shock—Lisinopril—coronary artery disease	5.23e-05	0.000275	CcSEcCtD
Naratriptan—Asthenia—Perindopril—coronary artery disease	5.23e-05	0.000275	CcSEcCtD
Naratriptan—Dyspnoea—Ramipril—coronary artery disease	5.23e-05	0.000275	CcSEcCtD
Naratriptan—Vomiting—Niacin—coronary artery disease	5.23e-05	0.000275	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Timolol—coronary artery disease	5.22e-05	0.000275	CcSEcCtD
Naratriptan—Hypersensitivity—Furosemide—coronary artery disease	5.22e-05	0.000274	CcSEcCtD
Naratriptan—Somnolence—Ramipril—coronary artery disease	5.21e-05	0.000274	CcSEcCtD
Naratriptan—Thrombocytopenia—Lisinopril—coronary artery disease	5.2e-05	0.000274	CcSEcCtD
Naratriptan—Dizziness—Trandolapril—coronary artery disease	5.2e-05	0.000273	CcSEcCtD
Naratriptan—Rash—Niacin—coronary artery disease	5.18e-05	0.000272	CcSEcCtD
Naratriptan—Dermatitis—Niacin—coronary artery disease	5.18e-05	0.000272	CcSEcCtD
Naratriptan—Dizziness—Enalapril—coronary artery disease	5.18e-05	0.000272	CcSEcCtD
Naratriptan—Skin disorder—Lisinopril—coronary artery disease	5.16e-05	0.000272	CcSEcCtD
Naratriptan—Pruritus—Perindopril—coronary artery disease	5.16e-05	0.000271	CcSEcCtD
Naratriptan—Headache—Niacin—coronary artery disease	5.15e-05	0.000271	CcSEcCtD
Naratriptan—Paraesthesia—Timolol—coronary artery disease	5.15e-05	0.000271	CcSEcCtD
Naratriptan—Vomiting—Pravastatin—coronary artery disease	5.14e-05	0.000271	CcSEcCtD
Naratriptan—Hyperhidrosis—Lisinopril—coronary artery disease	5.14e-05	0.00027	CcSEcCtD
Naratriptan—Diarrhoea—Captopril—coronary artery disease	5.14e-05	0.00027	CcSEcCtD
Naratriptan—Dyspnoea—Timolol—coronary artery disease	5.11e-05	0.000269	CcSEcCtD
Naratriptan—Dizziness—Telmisartan—coronary artery disease	5.1e-05	0.000268	CcSEcCtD
Naratriptan—Rash—Pravastatin—coronary artery disease	5.1e-05	0.000268	CcSEcCtD
Naratriptan—Dermatitis—Pravastatin—coronary artery disease	5.1e-05	0.000268	CcSEcCtD
Naratriptan—Somnolence—Timolol—coronary artery disease	5.09e-05	0.000268	CcSEcCtD
Naratriptan—Asthenia—Furosemide—coronary artery disease	5.08e-05	0.000267	CcSEcCtD
Naratriptan—Headache—Pravastatin—coronary artery disease	5.07e-05	0.000267	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Ramipril—coronary artery disease	5.06e-05	0.000266	CcSEcCtD
Naratriptan—Fatigue—Ramipril—coronary artery disease	5.05e-05	0.000266	CcSEcCtD
Naratriptan—Hypersensitivity—Losartan—coronary artery disease	5.04e-05	0.000265	CcSEcCtD
Naratriptan—Nausea—Valsartan—coronary artery disease	5.02e-05	0.000264	CcSEcCtD
Naratriptan—Pruritus—Furosemide—coronary artery disease	5.01e-05	0.000264	CcSEcCtD
Naratriptan—Constipation—Ramipril—coronary artery disease	5.01e-05	0.000264	CcSEcCtD
Naratriptan—Nausea—Olmesartan—coronary artery disease	5e-05	0.000263	CcSEcCtD
Naratriptan—Vomiting—Trandolapril—coronary artery disease	5e-05	0.000263	CcSEcCtD
Naratriptan—Diarrhoea—Perindopril—coronary artery disease	4.99e-05	0.000262	CcSEcCtD
Naratriptan—Vomiting—Enalapril—coronary artery disease	4.98e-05	0.000262	CcSEcCtD
Naratriptan—Hypotension—Lisinopril—coronary artery disease	4.97e-05	0.000261	CcSEcCtD
Naratriptan—Dizziness—Captopril—coronary artery disease	4.96e-05	0.000261	CcSEcCtD
Naratriptan—Rash—Trandolapril—coronary artery disease	4.95e-05	0.000261	CcSEcCtD
Naratriptan—Dermatitis—Trandolapril—coronary artery disease	4.95e-05	0.00026	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Timolol—coronary artery disease	4.95e-05	0.00026	CcSEcCtD
Naratriptan—Fatigue—Timolol—coronary artery disease	4.94e-05	0.00026	CcSEcCtD
Naratriptan—Rash—Enalapril—coronary artery disease	4.93e-05	0.000259	CcSEcCtD
Naratriptan—Dermatitis—Enalapril—coronary artery disease	4.93e-05	0.000259	CcSEcCtD
Naratriptan—Headache—Trandolapril—coronary artery disease	4.92e-05	0.000259	CcSEcCtD
Naratriptan—Vomiting—Telmisartan—coronary artery disease	4.91e-05	0.000258	CcSEcCtD
Naratriptan—Asthenia—Losartan—coronary artery disease	4.9e-05	0.000258	CcSEcCtD
Naratriptan—Headache—Enalapril—coronary artery disease	4.9e-05	0.000258	CcSEcCtD
Naratriptan—Pain—Timolol—coronary artery disease	4.9e-05	0.000258	CcSEcCtD
Naratriptan—Nausea—Niacin—coronary artery disease	4.88e-05	0.000257	CcSEcCtD
Naratriptan—Rash—Telmisartan—coronary artery disease	4.87e-05	0.000256	CcSEcCtD
Naratriptan—Dermatitis—Telmisartan—coronary artery disease	4.86e-05	0.000256	CcSEcCtD
Naratriptan—Diarrhoea—Furosemide—coronary artery disease	4.85e-05	0.000255	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Lisinopril—coronary artery disease	4.84e-05	0.000255	CcSEcCtD
Naratriptan—Pruritus—Losartan—coronary artery disease	4.84e-05	0.000254	CcSEcCtD
Naratriptan—Headache—Telmisartan—coronary artery disease	4.84e-05	0.000254	CcSEcCtD
Naratriptan—Feeling abnormal—Ramipril—coronary artery disease	4.83e-05	0.000254	CcSEcCtD
Naratriptan—Dizziness—Perindopril—coronary artery disease	4.82e-05	0.000253	CcSEcCtD
Naratriptan—Nausea—Pravastatin—coronary artery disease	4.81e-05	0.000253	CcSEcCtD
Naratriptan—Paraesthesia—Lisinopril—coronary artery disease	4.77e-05	0.000251	CcSEcCtD
Naratriptan—Vomiting—Captopril—coronary artery disease	4.77e-05	0.000251	CcSEcCtD
Naratriptan—Dyspnoea—Lisinopril—coronary artery disease	4.74e-05	0.000249	CcSEcCtD
Naratriptan—Rash—Captopril—coronary artery disease	4.73e-05	0.000249	CcSEcCtD
Naratriptan—Dermatitis—Captopril—coronary artery disease	4.73e-05	0.000249	CcSEcCtD
Naratriptan—Somnolence—Lisinopril—coronary artery disease	4.73e-05	0.000249	CcSEcCtD
Naratriptan—Feeling abnormal—Timolol—coronary artery disease	4.72e-05	0.000248	CcSEcCtD
Naratriptan—Headache—Captopril—coronary artery disease	4.7e-05	0.000247	CcSEcCtD
Naratriptan—Dizziness—Furosemide—coronary artery disease	4.68e-05	0.000246	CcSEcCtD
Naratriptan—Diarrhoea—Losartan—coronary artery disease	4.68e-05	0.000246	CcSEcCtD
Naratriptan—Nausea—Trandolapril—coronary artery disease	4.67e-05	0.000245	CcSEcCtD
Naratriptan—Urticaria—Ramipril—coronary artery disease	4.66e-05	0.000245	CcSEcCtD
Naratriptan—Nausea—Enalapril—coronary artery disease	4.65e-05	0.000244	CcSEcCtD
Naratriptan—Vomiting—Perindopril—coronary artery disease	4.63e-05	0.000244	CcSEcCtD
Naratriptan—Body temperature increased—Ramipril—coronary artery disease	4.63e-05	0.000244	CcSEcCtD
Naratriptan—Rash—Perindopril—coronary artery disease	4.6e-05	0.000242	CcSEcCtD
Naratriptan—Dermatitis—Perindopril—coronary artery disease	4.59e-05	0.000241	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Lisinopril—coronary artery disease	4.59e-05	0.000241	CcSEcCtD
Naratriptan—Nausea—Telmisartan—coronary artery disease	4.59e-05	0.000241	CcSEcCtD
Naratriptan—Fatigue—Lisinopril—coronary artery disease	4.58e-05	0.000241	CcSEcCtD
Naratriptan—Headache—Perindopril—coronary artery disease	4.57e-05	0.00024	CcSEcCtD
Naratriptan—Urticaria—Timolol—coronary artery disease	4.55e-05	0.000239	CcSEcCtD
Naratriptan—Pain—Lisinopril—coronary artery disease	4.55e-05	0.000239	CcSEcCtD
Naratriptan—Constipation—Lisinopril—coronary artery disease	4.55e-05	0.000239	CcSEcCtD
Naratriptan—Body temperature increased—Timolol—coronary artery disease	4.53e-05	0.000238	CcSEcCtD
Naratriptan—Dizziness—Losartan—coronary artery disease	4.52e-05	0.000238	CcSEcCtD
Naratriptan—Vomiting—Furosemide—coronary artery disease	4.5e-05	0.000237	CcSEcCtD
Naratriptan—Rash—Furosemide—coronary artery disease	4.47e-05	0.000235	CcSEcCtD
Naratriptan—Dermatitis—Furosemide—coronary artery disease	4.46e-05	0.000235	CcSEcCtD
Naratriptan—Nausea—Captopril—coronary artery disease	4.46e-05	0.000234	CcSEcCtD
Naratriptan—Headache—Furosemide—coronary artery disease	4.44e-05	0.000233	CcSEcCtD
Naratriptan—Feeling abnormal—Lisinopril—coronary artery disease	4.38e-05	0.00023	CcSEcCtD
Naratriptan—Vomiting—Losartan—coronary artery disease	4.35e-05	0.000229	CcSEcCtD
Naratriptan—Nausea—Perindopril—coronary artery disease	4.33e-05	0.000228	CcSEcCtD
Naratriptan—Hypersensitivity—Ramipril—coronary artery disease	4.32e-05	0.000227	CcSEcCtD
Naratriptan—Rash—Losartan—coronary artery disease	4.31e-05	0.000227	CcSEcCtD
Naratriptan—Dermatitis—Losartan—coronary artery disease	4.31e-05	0.000226	CcSEcCtD
Naratriptan—Headache—Losartan—coronary artery disease	4.28e-05	0.000225	CcSEcCtD
Naratriptan—Urticaria—Lisinopril—coronary artery disease	4.22e-05	0.000222	CcSEcCtD
Naratriptan—Hypersensitivity—Timolol—coronary artery disease	4.22e-05	0.000222	CcSEcCtD
Naratriptan—Nausea—Furosemide—coronary artery disease	4.21e-05	0.000221	CcSEcCtD
Naratriptan—Asthenia—Ramipril—coronary artery disease	4.21e-05	0.000221	CcSEcCtD
Naratriptan—Body temperature increased—Lisinopril—coronary artery disease	4.2e-05	0.000221	CcSEcCtD
Naratriptan—Pruritus—Ramipril—coronary artery disease	4.15e-05	0.000218	CcSEcCtD
Naratriptan—Asthenia—Timolol—coronary artery disease	4.11e-05	0.000216	CcSEcCtD
Naratriptan—Nausea—Losartan—coronary artery disease	4.06e-05	0.000214	CcSEcCtD
Naratriptan—Pruritus—Timolol—coronary artery disease	4.05e-05	0.000213	CcSEcCtD
Naratriptan—Diarrhoea—Ramipril—coronary artery disease	4.01e-05	0.000211	CcSEcCtD
Naratriptan—Diarrhoea—Timolol—coronary artery disease	3.92e-05	0.000206	CcSEcCtD
Naratriptan—Hypersensitivity—Lisinopril—coronary artery disease	3.92e-05	0.000206	CcSEcCtD
Naratriptan—Dizziness—Ramipril—coronary artery disease	3.88e-05	0.000204	CcSEcCtD
Naratriptan—Asthenia—Lisinopril—coronary artery disease	3.81e-05	0.000201	CcSEcCtD
Naratriptan—Dizziness—Timolol—coronary artery disease	3.79e-05	0.000199	CcSEcCtD
Naratriptan—Pruritus—Lisinopril—coronary artery disease	3.76e-05	0.000198	CcSEcCtD
Naratriptan—Vomiting—Ramipril—coronary artery disease	3.73e-05	0.000196	CcSEcCtD
Naratriptan—Rash—Ramipril—coronary artery disease	3.7e-05	0.000194	CcSEcCtD
Naratriptan—Dermatitis—Ramipril—coronary artery disease	3.69e-05	0.000194	CcSEcCtD
Naratriptan—Headache—Ramipril—coronary artery disease	3.67e-05	0.000193	CcSEcCtD
Naratriptan—Vomiting—Timolol—coronary artery disease	3.64e-05	0.000192	CcSEcCtD
Naratriptan—Diarrhoea—Lisinopril—coronary artery disease	3.64e-05	0.000191	CcSEcCtD
Naratriptan—Rash—Timolol—coronary artery disease	3.61e-05	0.00019	CcSEcCtD
Naratriptan—Dermatitis—Timolol—coronary artery disease	3.61e-05	0.00019	CcSEcCtD
Naratriptan—Headache—Timolol—coronary artery disease	3.59e-05	0.000189	CcSEcCtD
Naratriptan—Dizziness—Lisinopril—coronary artery disease	3.52e-05	0.000185	CcSEcCtD
Naratriptan—Nausea—Ramipril—coronary artery disease	3.48e-05	0.000183	CcSEcCtD
Naratriptan—Nausea—Timolol—coronary artery disease	3.4e-05	0.000179	CcSEcCtD
Naratriptan—Vomiting—Lisinopril—coronary artery disease	3.38e-05	0.000178	CcSEcCtD
Naratriptan—Rash—Lisinopril—coronary artery disease	3.35e-05	0.000176	CcSEcCtD
Naratriptan—Dermatitis—Lisinopril—coronary artery disease	3.35e-05	0.000176	CcSEcCtD
Naratriptan—Headache—Lisinopril—coronary artery disease	3.33e-05	0.000175	CcSEcCtD
Naratriptan—Nausea—Lisinopril—coronary artery disease	3.16e-05	0.000166	CcSEcCtD
Naratriptan—HTR1D—Signaling Pathways—KITLG—coronary artery disease	8.78e-06	9.41e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TGFBR2—coronary artery disease	8.78e-06	9.41e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CCL2—coronary artery disease	8.73e-06	9.35e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PSMA6—coronary artery disease	8.73e-06	9.35e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PSMB5—coronary artery disease	8.73e-06	9.35e-05	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—F2—coronary artery disease	8.71e-06	9.33e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—APOB—coronary artery disease	8.71e-06	9.33e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—SOCS3—coronary artery disease	8.7e-06	9.32e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IL6R—coronary artery disease	8.7e-06	9.32e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—KITLG—coronary artery disease	8.6e-06	9.21e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TGFBR2—coronary artery disease	8.6e-06	9.21e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—STAT5A—coronary artery disease	8.58e-06	9.2e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MMP3—coronary artery disease	8.58e-06	9.2e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IGF1—coronary artery disease	8.58e-06	9.19e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—AGT—coronary artery disease	8.56e-06	9.17e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—MAPK1—coronary artery disease	8.54e-06	9.15e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GSTM1—coronary artery disease	8.47e-06	9.07e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EDNRA—coronary artery disease	8.45e-06	9.05e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ADRB1—coronary artery disease	8.41e-06	9.01e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CYBA—coronary artery disease	8.41e-06	9.01e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MMP3—coronary artery disease	8.4e-06	9e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—STAT5A—coronary artery disease	8.4e-06	9e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—DUSP6—coronary artery disease	8.37e-06	8.97e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—LPL—coronary artery disease	8.31e-06	8.91e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—APOB—coronary artery disease	8.3e-06	8.89e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PLAT—coronary artery disease	8.23e-06	8.82e-05	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—CXCL8—coronary artery disease	8.23e-06	8.81e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—JAK2—coronary artery disease	8.18e-06	8.77e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—EDN1—coronary artery disease	8.16e-06	8.75e-05	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—PIK3CA—coronary artery disease	8.16e-06	8.74e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—SERPINE1—coronary artery disease	8.15e-06	8.73e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—APOB—coronary artery disease	8.12e-06	8.7e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GPX1—coronary artery disease	8.11e-06	8.69e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCL5—coronary artery disease	8.1e-06	8.68e-05	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CXCL8—coronary artery disease	8.05e-06	8.63e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—JAK2—coronary artery disease	8.01e-06	8.59e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—EDN1—coronary artery disease	7.99e-06	8.56e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—FGF1—coronary artery disease	7.98e-06	8.55e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CSF2—coronary artery disease	7.98e-06	8.55e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CXCL12—coronary artery disease	7.94e-06	8.51e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—BDKRB2—coronary artery disease	7.94e-06	8.51e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCL5—coronary artery disease	7.93e-06	8.5e-05	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—POMC—coronary artery disease	7.93e-06	8.5e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—LPL—coronary artery disease	7.92e-06	8.49e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—F2—coronary artery disease	7.91e-06	8.47e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CD36—coronary artery disease	7.9e-06	8.46e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—FGF2—coronary artery disease	7.89e-06	8.45e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL6ST—coronary artery disease	7.87e-06	8.44e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—RPS6KB1—coronary artery disease	7.85e-06	8.41e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MEF2C—coronary artery disease	7.85e-06	8.41e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—FGF1—coronary artery disease	7.81e-06	8.37e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CSF2—coronary artery disease	7.81e-06	8.37e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PPP2CA—coronary artery disease	7.8e-06	8.36e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—JUNB—coronary artery disease	7.8e-06	8.35e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—NOS3—coronary artery disease	7.78e-06	8.33e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PLCB1—coronary artery disease	7.77e-06	8.32e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—LPL—coronary artery disease	7.76e-06	8.31e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—RPS6KB1—coronary artery disease	7.69e-06	8.24e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MEF2C—coronary artery disease	7.69e-06	8.24e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ITGB3—coronary artery disease	7.65e-06	8.2e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HTR7—coronary artery disease	7.61e-06	8.15e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—JAK2—coronary artery disease	7.56e-06	8.1e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ITGB3—coronary artery disease	7.49e-06	8.03e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—MTHFR—coronary artery disease	7.48e-06	8.02e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CXCL8—coronary artery disease	7.47e-06	8e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PPP2CA—coronary artery disease	7.43e-06	7.96e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—PIK3CA—coronary artery disease	7.41e-06	7.94e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CXCL8—coronary artery disease	7.31e-06	7.84e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PRKCD—coronary artery disease	7.3e-06	7.82e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PPP2CA—coronary artery disease	7.28e-06	7.8e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ITGAV—coronary artery disease	7.25e-06	7.77e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KNG1—coronary artery disease	7.23e-06	7.74e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—POMC—coronary artery disease	7.2e-06	7.72e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CREB1—coronary artery disease	7.2e-06	7.72e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—AGTR1—coronary artery disease	7.18e-06	7.7e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PRKCD—coronary artery disease	7.15e-06	7.66e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—HTR2A—coronary artery disease	7.14e-06	7.65e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—C3—coronary artery disease	7.13e-06	7.64e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—AGT—coronary artery disease	7.11e-06	7.62e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CCL2—coronary artery disease	7.05e-06	7.55e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL6R—coronary artery disease	7.03e-06	7.53e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CXCL10—coronary artery disease	7.02e-06	7.52e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PLG—coronary artery disease	7e-06	7.5e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—HTR2A—coronary artery disease	6.99e-06	7.49e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—C3—coronary artery disease	6.98e-06	7.48e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—APOE—coronary artery disease	6.97e-06	7.47e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CXCL8—coronary artery disease	6.9e-06	7.39e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—APOA1—coronary artery disease	6.89e-06	7.38e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ADRB2—coronary artery disease	6.81e-06	7.3e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—HIF1A—coronary artery disease	6.8e-06	7.29e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—AGT—coronary artery disease	6.78e-06	7.26e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PRKCE—coronary artery disease	6.73e-06	7.21e-05	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—JAK2—coronary artery disease	6.72e-06	7.2e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SOCS1—coronary artery disease	6.71e-06	7.19e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—S100B—coronary artery disease	6.69e-06	7.17e-05	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—AKT1—coronary artery disease	6.67e-06	7.14e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—HIF1A—coronary artery disease	6.66e-06	7.14e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—APOE—coronary artery disease	6.64e-06	7.11e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—LEP—coronary artery disease	6.64e-06	7.11e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—AGT—coronary artery disease	6.64e-06	7.11e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SOCS3—coronary artery disease	6.63e-06	7.1e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CASP3—coronary artery disease	6.6e-06	7.08e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—APOA1—coronary artery disease	6.56e-06	7.03e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—IL6—coronary artery disease	6.56e-06	7.03e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TGFBR2—coronary artery disease	6.55e-06	7.02e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KITLG—coronary artery disease	6.55e-06	7.02e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—KDR—coronary artery disease	6.5e-06	6.97e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—LEP—coronary artery disease	6.5e-06	6.97e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—APOE—coronary artery disease	6.5e-06	6.97e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MAPK14—coronary artery disease	6.46e-06	6.92e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CCND1—coronary artery disease	6.43e-06	6.89e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—APOA1—coronary artery disease	6.43e-06	6.89e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MMP3—coronary artery disease	6.4e-06	6.86e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—STAT5A—coronary artery disease	6.4e-06	6.86e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—KDR—coronary artery disease	6.37e-06	6.82e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ESR1—coronary artery disease	6.34e-06	6.79e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MAPK14—coronary artery disease	6.33e-06	6.78e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—F2—coronary artery disease	6.26e-06	6.71e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—FN1—coronary artery disease	6.26e-06	6.71e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MMP9—coronary artery disease	6.24e-06	6.69e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL6ST—coronary artery disease	6.24e-06	6.68e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ESR1—coronary artery disease	6.21e-06	6.65e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—APOB—coronary artery disease	6.19e-06	6.63e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NFKBIA—coronary artery disease	6.19e-06	6.63e-05	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CXCL8—coronary artery disease	6.14e-06	6.57e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—F2—coronary artery disease	6.13e-06	6.57e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—FN1—coronary artery disease	6.13e-06	6.57e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL6ST—coronary artery disease	6.11e-06	6.54e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—JAK2—coronary artery disease	6.1e-06	6.54e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EDN1—coronary artery disease	6.09e-06	6.52e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PPARG—coronary artery disease	6.07e-06	6.5e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NFKBIA—coronary artery disease	6.06e-06	6.49e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—AKT1—coronary artery disease	6.05e-06	6.49e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCL5—coronary artery disease	6.04e-06	6.47e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—KIT—coronary artery disease	5.99e-06	6.42e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—POMC—coronary artery disease	5.99e-06	6.41e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CSF2—coronary artery disease	5.95e-06	6.38e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FGF1—coronary artery disease	5.95e-06	6.38e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—LPL—coronary artery disease	5.91e-06	6.33e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—KIT—coronary artery disease	5.87e-06	6.29e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—RPS6KB1—coronary artery disease	5.86e-06	6.27e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MEF2C—coronary artery disease	5.86e-06	6.27e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—GSK3B—coronary artery disease	5.75e-06	6.16e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ITGB3—coronary artery disease	5.71e-06	6.11e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—POMC—coronary artery disease	5.7e-06	6.11e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CREB1—coronary artery disease	5.7e-06	6.11e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—GSK3B—coronary artery disease	5.63e-06	6.03e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—VEGFA—coronary artery disease	5.6e-06	6e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—POMC—coronary artery disease	5.59e-06	5.98e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CREB1—coronary artery disease	5.59e-06	5.98e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCL2—coronary artery disease	5.58e-06	5.98e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CXCL8—coronary artery disease	5.57e-06	5.97e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL6R—coronary artery disease	5.56e-06	5.96e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PPP2CA—coronary artery disease	5.54e-06	5.94e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IGF1—coronary artery disease	5.49e-06	5.88e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCL2—coronary artery disease	5.46e-06	5.85e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—MAPK1—coronary artery disease	5.46e-06	5.85e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ALB—coronary artery disease	5.46e-06	5.85e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL6R—coronary artery disease	5.45e-06	5.84e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PRKCD—coronary artery disease	5.44e-06	5.83e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IGF1—coronary artery disease	5.37e-06	5.76e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—MAPK1—coronary artery disease	5.35e-06	5.73e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HTR2A—coronary artery disease	5.33e-06	5.71e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—C3—coronary artery disease	5.32e-06	5.7e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—NOS3—coronary artery disease	5.22e-06	5.59e-05	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—PIK3CA—coronary artery disease	5.22e-06	5.59e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—SERPINE1—coronary artery disease	5.21e-06	5.58e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—TGFB1—coronary artery disease	5.14e-06	5.51e-05	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—PIK3CA—coronary artery disease	5.11e-06	5.47e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—SERPINE1—coronary artery disease	5.1e-06	5.47e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HIF1A—coronary artery disease	5.07e-06	5.44e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—AGT—coronary artery disease	5.05e-06	5.42e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MAPK1—coronary artery disease	5.04e-06	5.4e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—FGF2—coronary artery disease	5.04e-06	5.4e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NOS3—coronary artery disease	4.97e-06	5.33e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—LEP—coronary artery disease	4.95e-06	5.31e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—APOE—coronary artery disease	4.95e-06	5.31e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—FGF2—coronary artery disease	4.94e-06	5.29e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—APOA1—coronary artery disease	4.9e-06	5.25e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NOS3—coronary artery disease	4.87e-06	5.22e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KDR—coronary artery disease	4.85e-06	5.2e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—JAK2—coronary artery disease	4.83e-06	5.18e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MAPK14—coronary artery disease	4.82e-06	5.16e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PTGS2—coronary artery disease	4.77e-06	5.12e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—PIK3CA—coronary artery disease	4.74e-06	5.08e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—JAK2—coronary artery disease	4.73e-06	5.07e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ESR1—coronary artery disease	4.73e-06	5.07e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—F2—coronary artery disease	4.67e-06	5e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FN1—coronary artery disease	4.67e-06	5e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL6ST—coronary artery disease	4.65e-06	4.98e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—PIK3CA—coronary artery disease	4.64e-06	4.97e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NFKBIA—coronary artery disease	4.62e-06	4.94e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KIT—coronary artery disease	4.47e-06	4.79e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CXCL8—coronary artery disease	4.41e-06	4.73e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PIK3CA—coronary artery disease	4.38e-06	4.69e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CXCL8—coronary artery disease	4.32e-06	4.63e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—GSK3B—coronary artery disease	4.29e-06	4.6e-05	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—AKT1—coronary artery disease	4.26e-06	4.57e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—POMC—coronary artery disease	4.25e-06	4.56e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CREB1—coronary artery disease	4.25e-06	4.56e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CASP3—coronary artery disease	4.22e-06	4.52e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—IL6—coronary artery disease	4.2e-06	4.5e-05	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—AKT1—coronary artery disease	4.17e-06	4.47e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCL2—coronary artery disease	4.16e-06	4.46e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL6R—coronary artery disease	4.15e-06	4.45e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CASP3—coronary artery disease	4.14e-06	4.43e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCND1—coronary artery disease	4.11e-06	4.4e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—IL6—coronary artery disease	4.11e-06	4.4e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IGF1—coronary artery disease	4.09e-06	4.38e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—MAPK1—coronary artery disease	4.07e-06	4.36e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCND1—coronary artery disease	4.03e-06	4.31e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MMP9—coronary artery disease	3.99e-06	4.28e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MMP9—coronary artery disease	3.91e-06	4.19e-05	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—PIK3CA—coronary artery disease	3.89e-06	4.17e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SERPINE1—coronary artery disease	3.89e-06	4.16e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IL6—coronary artery disease	3.88e-06	4.15e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—AKT1—coronary artery disease	3.87e-06	4.15e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—AKT1—coronary artery disease	3.79e-06	4.06e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FGF2—coronary artery disease	3.76e-06	4.03e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NOS3—coronary artery disease	3.71e-06	3.98e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—JAK2—coronary artery disease	3.61e-06	3.86e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—VEGFA—coronary artery disease	3.58e-06	3.84e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—AKT1—coronary artery disease	3.58e-06	3.83e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PIK3CA—coronary artery disease	3.53e-06	3.79e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—VEGFA—coronary artery disease	3.51e-06	3.76e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CXCL8—coronary artery disease	3.29e-06	3.53e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TGFB1—coronary artery disease	3.29e-06	3.52e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MAPK1—coronary artery disease	3.23e-06	3.46e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TGFB1—coronary artery disease	3.22e-06	3.45e-05	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—AKT1—coronary artery disease	3.18e-06	3.41e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MAPK1—coronary artery disease	3.16e-06	3.38e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CASP3—coronary artery disease	3.15e-06	3.38e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL6—coronary artery disease	3.13e-06	3.35e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCND1—coronary artery disease	3.07e-06	3.29e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MMP9—coronary artery disease	2.98e-06	3.19e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PIK3CA—coronary artery disease	2.94e-06	3.15e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—AKT1—coronary artery disease	2.89e-06	3.09e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PIK3CA—coronary artery disease	2.8e-06	3e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PIK3CA—coronary artery disease	2.74e-06	2.94e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—VEGFA—coronary artery disease	2.67e-06	2.86e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL6—coronary artery disease	2.48e-06	2.66e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TGFB1—coronary artery disease	2.45e-06	2.63e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL6—coronary artery disease	2.43e-06	2.6e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MAPK1—coronary artery disease	2.41e-06	2.58e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—AKT1—coronary artery disease	2.4e-06	2.57e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—AKT1—coronary artery disease	2.29e-06	2.45e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—AKT1—coronary artery disease	2.24e-06	2.4e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PIK3CA—coronary artery disease	2.09e-06	2.24e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL6—coronary artery disease	1.85e-06	1.98e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—AKT1—coronary artery disease	1.71e-06	1.83e-05	CbGpPWpGaD
